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Introduction
The average age of the world’s population is steadily increas-
ing, and so it is important to individuals, societies and the
global economy that the burden of age-related disease is re-
duced and healthspan (the proportion of a person’s life for
which he or she is healthy and active) is maximised.[1] Oxidative
stress is involved in almost all diseases in which age is the pri-
mary risk factor, including cardiovascular disease, neurodegen-
eration and stroke, and is implicated in the process of ageing
itself.[2] There is evidence that mitochondria are the main en-
dogenous source of the reactive oxygen species (ROS) that
give rise to this oxidative stress,[3] producing the first ROS, su-
peroxide (O2
·), as a side-product of oxidative phosphorylation
through incomplete reduction of molecular oxygen by elec-
trons leaked from complexes I, II and III of the electron-trans-
port chain (ETC).[4] Superoxide dismutase within the mitochon-
dria catalyses the rapid dismutation (disproportionation) of
superoxide to give oxygen and hydrogen peroxide. When H2O2
interacts with redox-active metal ions [e.g. , copper(I) and
iron(II)] , it produces highly reactive hydroxyl radicals by the
Fenton reaction, and these damage biomolecules. This ROS-
mediated damage can occur in the mitochondria themselves,
but also elsewhere, as H2O2 can readily diffuse across mito-
chondrial and cellular membranes. The body’s antioxidant de-
fence and repair mechanisms generally keep ROS-mediated
damage low, and H2O2 is an important signalling molecule for
maintaining homeostasis, but oxidative damage increases with
increasing age and does so dramatically in a wide range of
age-related pathologies. Indeed, a vicious cycle of oxidative
damage to mitochondrial DNA (mtDNA) resulting in a defective
ETC, which in turn gives higher ROS production,[3] has been
proposed as a mechanism of aging in some versions of the mi-
tochondrial free-radical theory of aging.[5]
Most cells have many mitochondria, and each of these mito-
chondria can have several copies of mtDNA. As a result, even
within a single cell, it is unlikely that mitochondrial damage
and dysfunction is homogeneous; instead, some mitochondria
function well, whereas others function poorly, and may be
preferentially cleared by mitophagy. We posed the question: is
it possible to modulate ROS production in the “misbehaving”
mitochondria without adversely affecting overall ATP produc-
tion or important ROS-dependent processes such as intracellu-
lar signalling[6] and immune responses?[7] Conceptually, we re-
quire functional molecules, which could be regarded as pro-
drugs, that accumulate in all mitochondria as a result of a tar-
geting group, but are activated through a ROS-dependent trig-
ger only in those mitochondria where ROS levels are high
enough to release molecules that moderate ROS production
(Figure 1). Thus, an instruction issued by an individual “misbe-
having” mitochondrion (i.e. , one producing high levels of ROS)
would induce a localised response. This strategy would com-
plement our recently reported externally instructed, mitochon-
A high membrane potential across the mitochondrial inner
membrane leads to the production of the reactive oxygen spe-
cies (ROS) implicated in aging and age-related diseases. A pro-
totypical drug for the correction of this type of mitochondrial
dysfunction is presented. MitoDNP-SUM accumulates in mito-
chondria in response to the membrane potential due to its mi-
tochondria-targeting alkyltriphenylphosphonium (TPP) cation
and is uncaged by endogenous hydrogen peroxide to release
the mitochondrial uncoupler, 2,4-dinitrophenol (DNP). DNP is
known to reduce the high membrane potential responsible for
the production of ROS. The approach potentially represents
a general method for the delivery of drugs to the mitochondri-
al matrix through mitochondria targeting and H2O2-induced
uncaging.
[a] S. J. McQuaker, Dr. S. T. Caldwell, Dr. R. C. Hartley
WestChem School of Chemistry, University of Glasgow
Glasgow, G12 8QQ (UK)
E-mail : Richard.Hartley@glasgow.ac.uk
[b] Dr. C. L. Quinlan, Prof. M. D. Brand
Buck Institute for Research on Aging
8001 Redwood Boulevard
Novato, California 94945 (USA)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201300115.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons At-
tribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 993 – 1000 993
CHEMBIOCHEM
FULL PAPERS
dria-targeted functional molecules, which release an active
compound within an individual mitochondrion with spatial
and temporal control in response to irradiation by a laser.[8]
Results and Discussion
The design of our prototypical molecule arises from the bio-
logical events at the mitochondrial inner membrane (MIM).
The ETC pumps protons out of the mitochondrial matrix into
the intermembrane space, and this leads to a proton motive
force (Dp) composed of a proton concentration gradient (DpH,
alkaline inside) and a membrane potential (Dy negative
inside) across the MIM. This drives the flow of protons back
into the matrix through ATP synthase powering ATP synthesis.
If Dp rises sufficiently, electron transport stalls ; thus leading to
high reduction of electron carriers in the chain, and reduction
of oxygen to superoxide at complexes I, II and III ;[4] this can
overwhelm the antioxidant defences. However, even a small
reduction in Dp is enough to greatly decrease ROS production,
particularly that caused by reversed electron tranport into
complex I.[9] Our prototypical small-molecule modulator or
selective uncoupling molecule (SUM), MitoDNP-SUM (Figure 2),
was designed to accumulate in the mitochondrial matrix, and
respond to H2O2 specifically in those mitochondria where the
ROS levels are high and respond by releasing a proton translo-
cator (an uncoupler) that would transport protons across the
MIM, thus reducing Dp (uncoupling electron tranport from ATP
synthase) and attenuating ROS production. MitoDNP-SUM
could be considered to be a small-molecule mimic of the mito-
chondrial proteins UCP2 and UCP3, which can cause mild un-
coupling in response to oxidative stress.[10]
MitoDNP-SUM (Figure 2) has three important functional fea-
tures: an alkyltriphenylphosphonium (TPP) group to target the
prodrug to the mitochondrial matrix ; an arylboronate group to
act as a H2O2-sensitive trigger; and a 2,4-dinitrophenoxyl group
that is a caged form of the classic uncoupler, 2,4-dinitrophenol
(DNP).
Lipophilic cations[11] and mitochondria-penetrating pep-
tides[12] are the best established methods of targeting small
molecules to the mitochondrion. The TPP group is cationic and
sufficiently lipophilic to diffuse across biological membranes,
so TPP compounds accumulate several hundred-fold in the mi-
tochondrial matrix as a result of the mitochondrial membrane
potential (Dy) in accordance with the Nernst equation.[11] Tests
on MitoQ (TPP attached to a ubiquinone moiety) show that
the TPP group does not adversely affect pharmacokinetics or
induce toxicity, as this TPP compound can be delivered effec-
tively by a variety of means, including orally, and without toxic-
ity.[11]
The reaction of arylboronates with H2O2 to give phenols is
the basis of a fluorescent probe[13] and a mass spectrometric
probe[14] for the measurement of H2O2 levels in the mitochon-
dria of cells and whole organisms, respectively. Another ROS,
peroxynitrite also induces this reaction,[15] but other biological
molecules do not convert arylboronates to phenols. MitoDNP-
SUM uses this reaction to induce fragmentation and release an
Figure 1. Prodrugs to correct dysfunctional mitochondria. The prodrug ac-
cummulates in all mitochondria because of its targeting group, but is only
activated in mitochondria where ROS levels are high, with uncaging trig-
gered by a ROS-sensitive group; the drug itself then interferes with the pro-
cess that is giving rise to ROS, so that normal ROS levels are restored within
the dysfunctional mitochondria.
Figure 2. Design features of MitoDNP-SUM.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 993 – 1000 994
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uncoupler, a trigger mechanism that was first demonstrated
for the H2O2-induced release of fluorophores.
[16] DNP was
chosen as the caged uncoupler; it is the classic example of an
uncoupler,[17] being a weak acid (pKa 4.1
[18]) and able to cross
membranes in both its protonated and deprotonated forms.[19]
Once released, DNP shuttles protons across the MIM by diffus-
ing into the mitochondrial matrix, releasing a proton and then
diffusing out again as the corresponding phenoxide (DNP) to
collect another proton. The uncoupler molecule is caged in
MitoDNP-SUM by attachment through its phenolic oxygen
atom to prevent uncoupling occuring prior to H2O2-triggered
release.
We have previously shown that the conversion of arylboro-
nate 1, which is related to phenoxide 2, leads to the release of
DNP with a second-order rate constant of (100.8)m1 s1
(Scheme 1).[20] Release of the uncoupler by this mechanism will
continue as long as there is high ROS production in the “mis-
behaving” mitochondrion, so the SUM should be effective
even though some uncoupler will diffuse away. In accordance
with the second-order rate equation, the rate of release will
drop in proportion to the falling [H2O2]. As a small reduction in
Dp is known to attenuate H2O2 production dramatically,
[9] un-
coupler release will be abruptly reduced to low levels as soon
as the [H2O2] in the mitochondrion drops. This means that the
selectivity for “misbehaving” mitochondria should be high,
with most mitochondria little affected by the SUM because
their [H2O2] will be low (the level in humans is not known, but
177 nm is a good estimate for average mitochondrial [H2O2] in
young Drosophila[14]). The targeted nature of MitoDNP-SUM is
also important in preventing off-target effects. Its concentra-
tion would be expected to be about 300 times higher in the
mitochondrion than in the cytosol. Reaction will also be faster
in the mitochondrion because the pH of the matrix is about
0.8 pH units higher than that of the cytosol, and the conjugate
base of H2O2 is the reactive species (Scheme 1).
[14] We have
previously demonstrated that the localised uncoupling of se-
lected mitochondria can be achieved by releasing DNP into
the matrix of these mitochondria through photo-uncaging of
a mitochondrion-targeted precursor.[8]
A two-carbon spacer group is positioned in MitoDNP-SUM
to ensure that nonspecific elimination of DNP is not encour-
aged by conjugation between the trigger and the central aro-
matic group. Synthetic considerations also played a part in the
design of MitoDNP-SUM. The use of an aryl ether link meant
that the targeting group would be introduced last and so
could potentially be varied, and the xylyl group provided two
benzylic sites for SN2 reactions.
An earlier compound, MitoDNP (not shown), combines
a TPP-targeting group and dinitrophenol,[21] but differs from
MitoDNP-SUM (trigger and caged DNP shown) in two critical
ways: the dinitrophenol group is not caged, so it would affect
all mitochondria regardless of ROS production, and the dinitro-
phenol unit is permanently attached to the lipophilic cation.
The latter feature might explain the lack of efficacy of MitoDNP,
as efflux of the deprotonated MitoDNP from the matrix,
which would be necessary for proton translocation, would be
disfavoured by TPP. Here we demonstrate the unique respon-
sive nature of MitoDNP-SUM: it reacts with H2O2 made by
mitochondria to release enough DNP to give significant levels
of uncoupling.
MitoDNP-SUM was synthesised as shown in Scheme 2. The
arylboronate trigger of MitoDNP-SUM was installed by using
Baron and Knochel’s chemoselective magnesiation of aryl io-
dides.[22] First, monomagnesiation of 1,4-diiodobenzene (3) fol-
lowed by borylation gave arylboronate 4, then magnesiation
and reaction with aldehyde 5 gave alcohol 6. Nucleophilic aro-
matic substitution of the fluoride of 1-fluoro-2,4-dinitroben-
zene, followed by deprotection gave phenol 7, which incorpo-
rates the caged DNP and could potentially be attached to any
Scheme 1. H2O2 reacts with an arylboronate cage to release DNP.
Scheme 2. Synthesis of MitoDNP-SUM. a) iPrMgCl, LiCl, THF, 78 8C;
b) 78 8C to RT; c) THF, LiCl, iPrMgCl, 78 8C; d) 78 8C to RT; e) 1-fluoro-2,4-
dinitrobenzene, Et3N, acetone, 40 8C; f) HCl, MeOH/CH2Cl2, RT; g) Cs2CO3,
MeCN, RT.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 993 – 1000 995
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targeting group. This was then alkylated with TPP-bearing ben-
zylic bromide 8, easily prepared from a,a’-para-dibromoxylene
and triphenylphosphine, to give the target compound.
The design principles of MitoDNP-SUM are ideally tested in
isolated mitochondria. MitoDNP-SUM should accumulate in
energised mitochondria and release free DNP as a result of
high endogenous H2O2 production. In the test tube, we found
that free DNP is released from MitoDNP-SUM after exposure to
H2O2 (Figure 3).
In isolated mitochondria, the uptake of MitoDNP-SUM was
monitored with an electrode sensitive to the TPP moiety. Mito-
chondria incubated in the presence of rotenone, an inhibitor
of complex I of the ETC, do not establish a membrane poten-
tial and do not take up MitoDNP-SUM (Figure 4A), but upon
addition of succinate, which is a substrate of complex II, the
inhibition is bypassed, and Dy drives uptake of the compound
as expected. The collapse of Dy induced by the uncoupler
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)
causes a release of the compound. Antimycin A inhibits com-
plex III of the ETC and prevents the generation of Dy in a way
that cannot be bypassed by these substrates of the ETC (Fig-
ure 4B). However, Dy can be generated by driving ATP syn-
thase in reverse through ATP hydrolysis, and this again leads
to the uptake of MitoDNP-SUM but in an ETC-independent
manner.
Building on these results, we designed an experiment to test
the H2O2-dependent uncoupling that would separate the two
important variables that determine uptake of MitoDNP-SUM
and release of free DNP: Dy and H2O2 production. The experi-
mental design, which is outlined in Figure 5, allows the same
Dy to be generated at both low and high rates of H2O2 pro-
duction. Complex III is inhibited by antimycin A, and Dy is es-
Figure 3. UV–visible spectra illustrating the H2O2 sensitivity of MitoDNP-SUM
in vitro. The H2O2-induced release of DNP was confirmed by comparing the
UV–visible spectra of 41.4 mm MitoDNP-SUM at 37 8C in aqueous KHE buffer
(2% acetonitrile) adjusted to pH 8.0 (the approximate pH of the mitochon-
drial matrix) with the same concentration of MitoDNP-SUM treated with
4 mm H2O2 for 15 min and with 41.4 mm of DNP in the same buffer system.
All experiments were carried out in triplicate, and the average is presented.
Figure 4. An electrode sensitive to the TPP moiety of MitoDNP-SUM was
conditioned in KHE buffer and 10 mm methyltriphenylphosphonium (TPMP)
for two weeks prior to the experiment, then washed extensively before use
to remove TPMP. Rat skeletal muscle mitochondria (0.3 mg protein per mL)
were incubated in KHE plus 0.3% (w/v) BSA with stirring at 37 8C. A) Two ali-
quots of 3 mm MitoDNP-SUM were added to the chamber, and mitochondrial
uptake was initiated by the addition of succinate (5 mm). Release of Mito-
DNP-SUM was instigated by the addition of FCCP (4 mm). B) Mitochondria
were incubated in the presence of antimycin A (2 mm). Two aliquots of 3 mm
MitoDNP-SUM were added to the chamber, and the mitochondria were
energised by hydrolysis of ATP (5 mm). Release was initiated by FCCP.
Figure 5. Experiment designed to test ROS-dependent uncoupling. A con-
stant membrane potential was generated by ATP hydrolysis. During ATP hy-
drolysis, in addition to vectorial proton pumping, scalar protons are liberat-
ed, and this results in net acid production and a corresponding drop in the
pH of the medium. In the basal state, Dp maintained by ATP hydrolysis is
high because of limited proton conductance, therefore ATP hydrolysis and
the net acidification of the medium are slow. The addition of an uncoupler
(DNP) will result in an increased rate of ATP hydrolysis because of increased
proton conductance. Under high-ROS conditions, greater uncoupling is ach-
ieved because more DNP is released from the MitoDNP-SUM. High-ROS con-
ditions were generated by incubating mitochondria with succinate (5 mm)
and antimycin A (2 mm), this led to superoxide production from complex
III.[23] Low-ROS conditions were created by omitting the succinate.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 993 – 1000 996
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tablished by ATP hydrolysis. In the absence of a substrate for
the ETC, there is no flow of electrons into the ETC and few
ROS are produced, but when succinate is added, the stalled
complex III generates a semiquinone, which reduces molecular
oxygen to superoxide, and this gives H2O2 and so high ROS
conditions.[23] Thus, ROS production in the presence of succi-
nate and antimycin A is divorced from the Dy generated by
ATP hydrolysis. This allows the Dy-driven uptake of the Mito-
DNP-SUM to be the same under the high and low ROS condi-
tions and alleviates concerns about differential accumulation
of MitoDNP-SUM under the two test conditions. The difference
in the rate of H2O2 production between the high and low ROS
conditions was approximately 30-fold (Figure 6).
Hydrolysis of ATP (in this case by ATP synthase acting in re-
verse) generates H+ . In the absence of an uncoupler, both ATP
hydrolysis and proton translocation through ATP synthase are
opposed by Dy, but in the presence of DNP, Dy is decreased,
and ATP hydrolysis leads to net acidification of the medium
outside the mitochondria. Thus, the rate of acidification reflects
the amount of DNP present. The dose-dependent degree of
ROS-induced uncoupling is summarised in Figure 7. There is
some background uncoupling at all doses, but at the 20 and
40 mm test doses, the release of free DNP and subsequent in-
crease in ATP hydrolysis was significantly greater under high-
ROS than under low-ROS conditions (p<0.05), and comparable
to the DNP control, thus showing that MitoDNP-SUM was suc-
cessfully triggered by endogenous H2O2 to induce uncoupling
in isolated mitochondria. Figure 8 illustrates this difference and
the method of measurement in the example of 20 mm Mito-
DNP-SUM under high- and low-ROS conditions.
Conclusions
Although there is some undesired background uncoupling in-
duced by MitoDNP-SUM, thus making it a prototype rather
than drug candidate, our study represents the first example of
a mitochondria-targeted prodrug that releases its payload in
direct response to mitochondria-generated ROS. MitoDNP-SUM
releases a molecule known to decrease ROS production by
lowering the membrane potential. Some H2O2 is produced by
all active mitochondria, but high membrane potential is be-
lieved to cause disproportionately high levels of ROS, so Mito-
DNP-SUM represents a prototypical drug for selectively correct-
ing the behaviour of dysfunctional mitochondria (where this
dysfunction arises from high membrane potential). In a wider
context, our approach provides a new way to deliver drugs
specifically to the mitochondrial matrix through a combination
of TPP targeting and ROS-induced uncaging.
Experimental Section
Synthesis : Aldehyde 5 was prepared from 3-(4-hydroxyphenyl)pro-
pionic acid according to the literature[24] (see the Supporting Infor-
mation for details). Other reagents were obtained from commercial
suppliers and used without further purification, unless otherwise
Figure 6. The rates of H2O2 production were monitored by using the Amplex
UltraRed detection system. The high- and low-ROS conditions were created
as described for Figure 5.
Figure 7. The rate of ATP hydrolysis initiated by uncoupling was measured
as the rate of decline in the medium pH upon addition of MitoDNP-SUM or
DNP. Experiments were performed in a Seahorse XF24 and calibrated by the
addition of a known amount of acid (see the Experimental Section). Results
represent meansS.E. The increased rate of ATP hydrolysis under high-ROS
conditions was statistically significant under the 20 and 40 mm test condi-
tions (p<0.05), as determined with a Student’s unpaired t-test.
Figure 8. The addition of MitoDNP-SUM to mitochondria led to different
rates of acidification depending on whether the experiment was conducted
under low- (*) or high-ROS (&) conditions. The rate of acidification was de-
termined by taking a linear regression of the grey shaded region on the
plot. The effect of FCCP is also shown, together with the inhibition of ATP
synthase by 1 mgmL1 oligomycin. Typically an acid calibration addition was
made at the end of multiple runs per plate, and the average pH change
(~0.15 pH units) was used to calibrate the data to pmol H+ ·min1 per mg
protein.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 993 – 1000 997
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stated. All reactions under an inert atmosphere were carried out in
oven- or flame-dried glassware. Solutions were added via a syringe.
Toluene and THF were dried, where necessary, by using a solvent
drying system, Puresolv, in which solvent is pushed from its stor-
age container under low nitrogen pressure through two stainless-
steel columns containing activated alumina and copper. Acetone
and triethylamine were dried by distillation from calcium sulfate
and potassium hydroxide, respectively. 1H, 31P and 13C NMR spectra
were obtained on a Bruker AVIII/500 spectrometer operating at
500, 202 and 125 MHz, respectively, or a Bruker DPX/400 spectrom-
eter operating at 400, 162 and 100 MHz, respectively. All coupling
constants are measured in Hz. Distortionless enhancement by
polarisation transfer (DEPT) was used to assign the signals in the
13C NMR spectra as C, CH, CH2 or CH3. ESI-MS was carried out on
a Thermofisher LTQ Orbitrap XL at the University of Swansea, other
mass spectra were recorded on a Jeol JMS700 (MStation) spec-
trometer. Infra-red spectra were obtained on a Shimadzu FTIR-
8400S spectrometer by using attenuated total reflectance (ATR), so
that the IR spectrum of the compound (solid or liquid) could be
directly detected (thin layer) without any sample preparation.
2-(4-Iodophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4): Anhy-
drous THF (500 mL) was added to 1,4-diiodobenzene (3 ; 25.00 g,
75.8 mmol) and anhydrous LiCl (3.48 g, 82.1 mmol) under argon.
The stirring mixture was cooled to 78 8C, and iPrMgCl (2.0m in
THF, 41 mL, 82 mmol) was added dropwise over 50 min. After the
solution had been stirred for 3 h at 78 8C, 2-isopropoxy-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (15.5 mL, 75.8 mmol) was added
dropwise, and the mixture was allowed to warm slowly to RT over-
night. Saturated aqueous NH4Cl (50 mL) was added to quench the
reaction. The resulting mixture was stirred until the precipitate
settled before being filtered through a pad of celite and washed
through with Et2O. Organics were dried over MgSO4 and concen-
trated under reduced pressure. Column chromatography (SiO2, pe-
troleum ether/EtOAc 9:1) yielded dioxaborolane 4 as a white solid
(24.58 g, 98%). M.p. 95–96 8C; Rf=0.45 (SiO2, petroleum ether/
EtOAc 9:1); 1H NMR (400 MHz, CDCl3): d=7.72 (d, J=8.2 Hz, 2H; H-
2’ and H-6’), 7.51 (d, J=8.1 Hz, 2H; H-3’ and H-5’), 1.33 ppm (s,
12H; 4Me); 13C NMR (100 MHz, CDCl3): d=136.90 (CH), 136.26
(CH), 98.83 (C), 84.01 (C), 24.84 ppm (CH3).
1H and 13C NMR data
agree with the literature.[22]
3-(4-Methoxymethoxyphenyl)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxabor-
olan-2-yl)phenyl]propan-1-ol (6): Anhydrous THF (60 mL) was added
to aryl iodide 4 (3.91 g, 11.8 mmol) and anhydrous LiCl (552 mg,
13.0 mmol) under argon. The stirring mixture was cooled to
78 8C, and iPrMgCl (2.0m in THF, 6.5 mL, 13.0 mmol) was added
dropwise over 20 min. After the mixture had been stirred for 3.5 h
at 78 8C, aldehyde 5[24] (1.64 g, 8.4 mmol) in anhydrous THF
(10 mL) was added dropwise, and the solution was allowed to
warm to RT overnight. Saturated aqueous NH4Cl (7 mL) was added
to quench the reaction. H2O (40 mL) was added, and the mixture
was extracted with Et2O (340 mL). Combined organics were fil-
tered through a pad of celite and washed with Et2O. Organics were
dried over MgSO4 and concentrated under reduced pressure.
Column chromatography (SiO2, petroleum ether/EtOAc 19:1 to
55:45) yielded alcohol 6 as a colourless oil (3.36 g, 93%). Rf=0.22
(SiO2, petroleum ether/EtOAc 4:1);
1H NMR (400 MHz, CDCl3): d=
7.78 (d, J=8.1 Hz, 2H; H-3’’ and H-5’’), 7.32 (d, J=8.0 Hz, 2H; H-2’’
and H-6’’), 7.07 (d, J=8.6 Hz, 2H; H-2’ and H-6’), 6.93 (d, J=8.6 Hz,
2H; H-3’ and H-5’), 5.11 (s, 2H; OCH2O), 4.68–4.60 (m, 1H; CHOH),
3.44 (s, 3H; OCH3), 2.70–2.52 (m, 2H; ArCH2), 2.33 (br s, 1H; OH),
2.12–1.87 (m, 2H; ArCH2CH2), 1.33 ppm (s, 12H; 4CH3);
13C NMR
(100 MHz, CDCl3): d=155.36 (C), 147.84 (C), 135.15 (C), 134.97 (CH),
129.34 (CH), 125.24 (CH), 116.25 (CH), 94.53 (CH2), 83.76 (C), 73.60
(CH), 55.85 (CH3), 40.57 (CH2), 31.06 (CH2), 24.83 ppm (CH3);
11B NMR (128 MHz, CDCl3): d=30.54 ppm (s); IR (ATR): n˜max=3458
(OH), 2979 (CH), 2932 (CH), 2865 (CH), 2826 (CH), 1611 (Ar),
1586 cm1 (Ar) ; LRMS (EI+): m/z (%): 398 (53) [M]+ , 380 (43)
[MH2O]+ , 233 (33) [(C6H12O2)B(C6H4)CHOH]+ , 230 (60), 165
[CH3OCH2O(C6H4)CH2CH2]
+ (10), 107 (45) [HOC6H4CH2]
+ , 45 (100)
[CH3OCH2]
+ ; HRMS: 398.2260, C23H31
11BO5 requires 398.2265 [M]
+ .
4-{3-(2,4-Dinitrophenoxy)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl]propyl}phenol (7): Anhydrous acetone (0.2 mL) was
added to a stirring solution of alcohol 6 (500 mg, 1.26 mmol), 1-
fluoro-2,4-dinitrobenzene (470 mL, 3.77 mmol) and anhydrous tri-
ethylamine (525 mL, 3.77 mmol) under argon. The resulting solution
was stirred at 40 8C for 72 h, then concentrated under reduced
pressure. EtOAc (12 mL) was added, and the solution was washed
with saturated aqueous NaHCO3 (6 mL) and H2O (26 mL). Organ-
ics were dried over MgSO4 and concentrated under reduced pres-
sure. CH2Cl2 (16 mL) and MeOH (16 mL) were added followed by
concentrated HCl (4 mL) dropwise. The resulting solution was
stirred at 32 8C for 3.5 h. Pinacol (35 mg, 296 mmol) and 4  molec-
ular sieves were added, and the mixture was stirred at RT for a
further 1 h. The solution was filtered, and sieves were washed with
CH2Cl2 (10 mL). Organics were poured into aqueous HCl (1m,
12 mL) and separated before the mixture was extracted with
CH2Cl2 (310 mL). Combined organics were dried over MgSO4 and
concentrated under reduced pressure. Column chromatography
(SiO2, petroleum ether/EtOAc 9:1 to 2:1) yielded phenol 7 as
a yellow oil (417 mg, 64%). Rf (SiO2, petroleum ether/EtOAc 7:3)=
0.33; 1H NMR (500 MHz, CDCl3): d=8.70 (d, J=2.8 Hz, 1H; H-3’’),
8.14 (dd, J=9.3, 2.8 Hz, 1H; H-5’’), 7.80 (d, J=7.9 Hz, 2H; H-3’’’ and
H-5’’’), 7.31 (d, J=8.0 Hz, 2H; H-2’’’ and H-6’’’), 7.02 (d, J=8.4 Hz,
2H; H-3 and H-5), 6.85 (d, J=9.4 Hz, 1H; H-6’’), 6.74 (d, J=8.4 Hz,
2H; H-2 and H-6), 5.25 (dd, J=8.4 and 4.5 Hz, 1H; CHODNB), 4.81
(br s, 1H; OH), 2.77 (t, J=7.5 Hz, 2H; ArCH2), 2.46–2.36 (m, 1H;
ArCH2CH
AHB), 2.21–2.11 (m, 1H; ArCH2CH
AHB), 1.33 (s, 6H; 2Me),
1.32 ppm (s, 6H; 2Me); 13C NMR (126 MHz, CDCl3): d=155.71 (C),
153.96 (C), 141.82 (C), 139.92 (C), 139.40 (C), 135.61 (CH), 132.59
(C), 129.60 (CH), 128.56 (CH), 125.10 (CH), 121.69 (CH), 116.00 (CH),
115.46 (CH), 84.06 (C), 82.12 (CH), 32.92 (CH2), 30.48 (CH2), 24.87
(CH3), 24.82 ppm (CH3); LRMS (EI
+): m/z (%): 520 (7) [M]+ , 336 (7)
[MDNP]+ , 184 (10) [DNP]+ , 107 (100) [HOArCH2]+ , 91 (16); HRMS:
520.2018 and 519.2049, C27H29
11BN2O8 requires 520.2017 [M]
+ and
C27H29
10BN2O8 requires 519.2053 [M]
+ .
[4-(Bromomethyl)benzyl]triphenylphosphonium bromide (8): A solu-
tion of triphenylphosphine (100 mg, 0.38 mmol) in anhydrous tolu-
ene (1.25 mL) was added dropwise to a stirring solution of a,a’-
para-dibromoxylene (604 mg, 2.3 mmol) in anhydrous toluene
(2.5 mL) at 95 8C under argon, and the resulting solution was
stirred for 1 h. A further solution of triphenylphosphine (100 mg,
0.38 mmol) in anhydrous toluene (2.5 mL) was added dropwise,
and the resulting mixture was stirred for 5 h at 95 8C under argon.
The hot mixture was filtered, and the precipitate was washed with
hot toluene and then Et2O. The solid was dried under reduced
pressure to yield phosphonium bromide 8 as a white amorphous
solid (391 mg, 98%). M.p.>220 8C (decomp.) ; 1H NMR (400 MHz,
CD3CN): d=7.91–7.84 (m, 3H; 3p-H PPh3), 7.72–7.64 (m, 6H; 6
o-H PPh3), 7.61–7.51 (m, 6H; 6m-H PPh3), 7.27 (d, J=7.7 Hz, 2H;
H-3 and H-5), 6.94 (dd, J=7.9, 1.8 Hz, 2H; H-2 and H-6), 4.68 (d, J=
14.3 Hz, 2H; CH2P), 4.52 ppm (s, 2H; CH2Br);
13C NMR (100 MHz,
CD3CN): d=138.89 (d, J=4.6 Hz, C), 134.95 (d, J=2.9 Hz, CH),
133.89 (d, J=9.8 Hz, CH), 131.01 (d, J=5.4 Hz, CH), 129.77 (d, J=
12.6 Hz, CH), 129.29 (d, J=3.0 Hz, CH), 127.21 (d, J=7.8 Hz, C),
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117.06 (d, J=86.0 Hz, C), 32.36 (s, CH2), 29.16 ppm (d, J=48.3 Hz,
CH2); {
1H}31P NMR (162 MHz, CD3CN): d=22.71 ppm (s) ; IR (ATR):
n˜max=3054 (CH), 3010 (CH), 2990 (CH), 2965 (CH), 2887 (CH), 2850
(CH), 2779 (CH), 1604 (Ar), 1588 (Ar), 1572 cm1 (Ar) ; LRMS (ESI+):
447 [cation (81Br), 100%], 445 [cation (79Br), 93] ; HRMS: 447.0683
and 445.0707, C26H26
81BrP requires cation, 447.0695 and C26H26
79BrP
requires cation, 445.0715; LRMS (ESI): 81 (81Br , 99%) and 79
(79Br , 100).
[(4-{4-(3-{2,4-Dinitrophenoxy}-3-{4-(4,4,5,5-tetramethyl-1,3,2-dioxabor-
olan-2-yl)phenyl}prop-1-yl)phenoxymethyl}phenyl)methyl]triphenyl-
phosphonium bromide (MitoDNP-SUM): Cs2CO3 (178 mg, 0.55 mmol)
was added to phenol 5 (178 mg, 0.34 mmol) in anhydrous MeCN
(1.2 mL), and the mixture was stirred under argon for 5 min. Ben-
zylic bromide 8 (180 mg, 0.34 mmol) in anhydrous CH2Cl2 (0.4 mL)
was added. The resulting solution was stirred at RT for 10.5 h
under argon before being concentrated under reduced pressure.
H2O (5 mL) was added, and the resulting solution was extracted
with CHCl3 (35 mL). Combined organics were dried over MgSO4
and concentrated under reduced pressure. The solid was dissolved
in CH2Cl2 and precipitated by being added dropwise to stirring
Et2O. The liquor was pipetted off, and the solid was washed with
Et2O. Column chromatography of the residual solid (SiO2, CH2Cl2/
EtOH 9:1) yielded MitoDNP-SUM as a yellow amorphous solid
(192 mg, 58%). Rf (SiO2, CH2Cl2/EtOH 9:1)=0.20;
1H NMR (500 MHz,
CDCl3): d=8.69 (d, J=2.8 Hz, 1H; H-3’’’), 8.14 (dd, J=9.3 and
2.8 Hz, 1H; H-5’’’), 7.82–7.72 (m, 11H; 6o-H PPh3, 3p-H PPh3, H-
3 and H-5), 7.66–7.59 (m, 6H; 6m-H PPh3), 7.31 (d, J=8.1 Hz, 2H;
H-3’’’’ and H-5’’’’), 7.19 (d, J=8.0 Hz, 2H; H-2’’’’ and H-6’’’’), 7.13
(dd, J=8.3, 2.8 Hz, 2H; H-2 and H-6), 7.05 (d, J=8.7 Hz, 2H; H-3’
and H-5’), 6.86 (d, J=9.4 Hz, 1H; H-6’’’), 6.81 (d, J=8.7 Hz, 2H; H-2’
and H-6’), 5.50–5.42 (m, 2H; CH2P), 5.26 (dd, J=8.4, 4.5 Hz, 1H; H-
3’’), 4.96 (d, J=2.0 Hz, 2H; CH2O), 2.77 (t, J=7.5 Hz, 2H; H-1’’),
2.45–2.36 (m, 1H; HA-2’’), 2.21–2.12 (m, 1H; HB-2’’), 1.324 (s, 6H; 2
Me), 1.319 ppm (s, 6H; 2Me);13C NMR (126 MHz, CDCl3): d=
156.86 (C), 155.73 (C), 141.79 (C), 139.77 (C), 139.22 (C), 137.53 (d,
J=4.2 Hz, C), 135.54 (CH), 135.07 (d, J=2.4 Hz, CH), 134.32 (d, J=
9.8 Hz, CH), 133.05 (C), 131.63 (d, J=5.6 Hz, CH), 130.18 (d, J=
12.7 Hz, CH), 129.41 (CH), 128.72 (CH), 127.66 (d, J=3.0 Hz, CH),
126.62 (d, J=8.6 Hz, C), 125.14 (CH), 121.59 (CH), 117.61 (d, J=
85.6 Hz, C), 116.32 (CH), 114.95 (CH), 83.99 (C), 82.10 (CH), 69.29
(CH2), 39.89 (CH2), 30.49 (d, J=47.3 Hz, CH2), 30.46 (CH2), 24.86
(CH3), 24.81 ppm (CH3); {
1H}31P NMR (162 MHz, CDCl3): d=
23.00 ppm (s) ; IR (ATR): n˜max=3059 (CH), 3051 (CH), 2978 (CH),
2918 (CH), 2868 (CH), 2853 (CH), 1605 (Ar), 1524 (Ar), 1510 (Ar) ;
LRMS (ESI+): 885 (cation, 100%); HRMS (ESI+): 885.3478 and
884.3517. C53H51
11BN2O8P requires cation, 885.3479 and
C53H51
10BN2O8P requires cation, 884.3507; LRMS (ESI
): 81 (81Br ,
98%) and 79 (79Br , 100).
Biology
Animals, reagents and mitochondrial preparation: Female Wister
rats (Harlan Laboratories), age 5–8 weeks, were fed chow ad libi-
tum with free access to water. Skeletal muscle mitochondria were
isolated at 4 8C in Chappell–Perry buffer (CP1; 100 mm KCl, 50 mm
Tris, 2 mm ethylene glycol tetraacetic acid (EGTA), pH 7.1 at 25 8C)
by standard procedures.[25] The animal protocol was approved by
the Buck Institute Animal Care and Use Committee, in accordance
with IACUC standards. All reagents were purchased from Sigma–
Aldrich except Amplex UltraRed, which was purchased from Invi-
trogen.
Superoxide and H2O2 production by isolated mitochondria: The com-
bined superoxide and H2O2 production rates were measured as
H2O2 production rate after dismutation of superoxide by endoge-
nous superoxide dismutase. H2O2 production rates were deter-
mined by using the Amplex UltraRed detection system in a Cary
Varian spectrofluorometer at the wavelength couple lex=560 nm,
lem=590 nm. Horseradish peroxidase was added to catalyse re-
action of extramitochondrial H2O2 with Amplex UltraRed to form a
fluorescent resorufin product. Mitochondria (0.3 mg protein per
mL) were incubated at 37 8C in standard medium containing KCl
(120 mm), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES, 5 mm), EGTA (1 mm, pH 7.2 at 20 8C) and bovine serum al-
bumin (0.3%, w/v). All assays contained Amplex UltraRed (50 mm)
and horseradish peroxidase (5 units per mL). Fluorescence emission
data were calibrated from H2O2 standard curves obtained under
identical conditions.
Methyltriphenylphosphonium (TPMP) electrode detection of MitoDNP-
SUM uptake: TPMP electrodes were prepared exactly as described
in the literature.[25] Skeletal muscle mitochondria were incubated
under similar conditions as for H2O2 production measurements at
37 8C in KHE medium. Succinate oxidation generated a Dp of
~180 mV, and ATP hydrolysis routinely generated a Dp of
~140 mV; these were measured by using TPMP distribution in the
presence of nigericin (100 nm) and were similar to values in the lit-
erature.[26] The uptake of MitoDNP-SUM was monitored after addi-
tion of the compound (23 mm). Higher concentrations and more
additions could not be assessed because high amounts of Mito-
DNP-SUM interfered with the TPMP electrode.
MitoDNP-SUM ROS-dependent uncoupling: All uncoupling assays
were performed by using a Seahorse XF24 Extracellular Flux Ana-
lyzer (Seahorse Bioscience). The instrument assays O2 and H
+ levels
by using fluorescent probes on a sensor cartridge that lowers to
within 200 mm of the well bottom during a measurement cycle,
thereby creating a trapped volume (7 mL) in which the measure-
ment is made. Isolated skeletal muscle mitochondria (5 mg per
well) were spun down onto 24-well plates exactly as described in
the literature.[27] The assay was performed in standard KHE medium
containing ATP (5 mm), antimycin A (2 mm), and the presence or
absence of succinate created the high- or low-ROS conditions, as
described above. The medium was maintained at pH 6.8 and 37 8C.
The XF24 cartridge has four reagent delivery ports per well for in-
jecting compounds into the wells during an assay. MitoDNP-SUM
was injected at the first port, and ATP hydrolysis was monitored as
a drop in pH over time (3 min). In multiple wells on the plate, HCl
(37.5 nmol) was added at the end of the experiment to acidify the
solution by about 0.15 pH units as an acid calibration point, and
data were converted to pmol H+ ·min1 per mg protein.
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